Provided by Tiger Trade Technology Pte. Ltd.

Agree

75.94
-0.5750-0.75%
Volume:140.32K
Turnover:10.67M
Market Cap:8.73B
PE:44.35
High:76.79
Open:76.79
Low:75.44
Close:76.51
52wk High:79.65
52wk Low:68.98
Shares:114.93M
Float Shares:108.37M
Volume Ratio:0.92
T/O Rate:0.13%
Dividend:3.05
Dividend Rate:4.02%
EPS(TTM):1.71
EPS(LYR):1.78
ROE:3.48%
ROA:2.33%
PB:1.53
PE(LYR):42.66

Loading ...

Evercore ISI Sticks to Their Buy Rating for Agree Realty (ADC)

TIPRANKS
·
33 mins ago

Akari Therapeutics Participates in Virtual Investor “What This Means” Interview Discussing the Company’s Expanded ADC Pipeline

GlobeNewswire
·
1 hour ago

Sutro Biopharma Highlights ADC Platform in New Presentation

TIPRANKS
·
16 hours ago

GUIDANCE: (ADC) Agree Realty Expects Full Year 2026 AFFO Range $4.54 - $4.58

MT Newswires Live
·
17 hours ago

Agree Realty Q4 net income per share rises

Reuters
·
18 hours ago

Agree Realty reports Q4 AFFO $1.11, consensus $1.10

TIPRANKS
·
18 hours ago

Agree Realty sees FY26 AFFO $4.54-$4.58, consensus $4.53

TIPRANKS
·
18 hours ago

ADC Q4 net income attributable to common stockholders at USD 54.18 million, up 25%

Reuters
·
18 hours ago

Agree Realty Q4 FFO $1.11 Beats $1.10 Estimate, Sales $190.489M Beat $185.501M Estimate

Benzinga
·
18 hours ago

BRIEF-Agree Realty Q4 Core FFO Per Share USD 1.1

Reuters
·
18 hours ago

Agree Realty Outlook FY Adjusted Ffo per Share USD 4.54-4.58

THOMSON REUTERS
·
18 hours ago

Agree Realty: on Track to Achieve 2026 Affo per Share Guidance of $4.54 to $4.58

THOMSON REUTERS
·
18 hours ago

Agree Realty Q4 Core Ffo USD 126.8 Million

THOMSON REUTERS
·
18 hours ago

U.S. Earnings Preview: After Market Close Feb. 10

Dow Jones
·
18 hours ago

Defence Therapeutics Refines Accum ADC Strategy With New Scientific Advisory Board

TIPRANKS
·
Yesterday

Day One To Report Fourth Quarter and Full-Year 2025 Financial Results Tuesday, February 24, 2026

GlobeNewswire
·
Yesterday

Press Release: Sutro Biopharma Announces Pricing of $110.0 million Underwritten Offering

Dow Jones
·
Yesterday

Southwest Securities: Broad Market Potential for Driver Gene-Negative NSCLC, with Dual/Multi-Specific Antibodies and IO+ADC Therapies Advancing Together

Stock News
·
Yesterday

Why Doctors Can't Agree on How to Diagnose Alzheimer's -- Your Health -- WSJ

Dow Jones
·
Yesterday

Chinese Pharmaceutical Firm Completes Patient Enrollment for Phase III Trial of HER2-Targeting Drug

Stock News
·
Yesterday